2027 Annual Symposium - The Society of Toxicologic Pathology (STP)
2027 STP Annual Symposium

Program

STP 46TH ANNUAL SYMPOSIUM PROGRAM

The Pathobiology of Neoplasia from Cause to Cure

Scientific Co-Chairs: Alix D. Rogers, BVMS, MRCVS, PhD, DACVP, Assoc. FIATP, Charles River Laboratories; Stacey Fossey, DVM, PhD, DACVP, DABT, FIATP, AbbVie; and John Vahle, DVM, PhD, DACVP, Eli Lilly

Continuing Education Chair: Saravanan Kaliyaperumal, BVSc & AH, MPH, PhD, DACVP, DABT, J&J Innovative Medicine.

Continuing Education Co-Chair: Karyn E. Enos, DVM, MS, DACVP, Novartis

The topic of the 46th Annual Symposium on June 27–30, 2027 in Denver, CO, is “The Pathobiology of Neoplasia from Cause to Cure.” Themes encompass cancer biology and mechanisms, cancer therapeutics and their safety assessment, as well as carcinogenicity risk assessment. Sessions will provide an overview of the latest scientific understanding of mechanisms of neoplasia as well as practical content for the toxicologic pathologists involved in risk assessment to include weight of evidence assessments and regulatory perspectives.

We are pleased to welcome Dr. Heide Ford, PhD to deliver the Keynote address. Dr. Ford is Professor and Colorado University Medicine Endowed Chair in Pharmacology with considerable experience in the field of drug discovery and cancer research using innovative gene therapy to minimize drug-related toxicity with pathology assessment in animal models. This will set the stage for sessions addressing novel cancer therapeutics and toxicity, as well as new methods for addressing carcinogenicity assessment.

The first scientific session co-chaired by Drs. Dinesh Bangari, BVSc, MVSc, MS, PhD, DACVP, and Anoop Kavirayani, BVSc, DACVP, will focus on cancer biology and mechanisms, including talks on novel targets, translational cancer biology, and case studies in anatomic and clinical pathology. In the afternoon session chaired by Drs. Elizabeth Clark, DVM, PhD, DACVP, and Famke Aeffner, DVM, PhD, DACVP, DABT, FIATP, speakers will share talks on various novel cancer therapeutics ranging from novel antibody-drug payloads to in vivo animal models and leveraging ‘omics in drug discovery. The session on Tuesday will be chaired by Drs. Aaron Sargeant, DVM, PhD, DACVP, and Daher Ibrahim Aibo, DVM, PhD, DACVP, and discuss safety assessment of oncology therapeutics such as CAR-T, B-cell depleters, targeted protein degraders, and radioligands.

The Wednesday morning session chaired by Drs. Arun Pandiri, BVSc & AH, MS, PhD, and Thomas Nolte, DVM, PhD, will focus on new approaches for carcinogenicity risk assessment and include topics such as integration of molecular data for hazard identification, and experience with weight-of-evidence approaches from the pharmaceutical and agrochemical industries and government. The afternoon session chaired by Drs. David Garcia-Tapia, DVM, MS, PhD, DABT, DACVP, and Marie Bockenstedt, DVM, PhD, DACVP, DABT, will discuss the role of rodent carcinogenicity studies include study designs, rodent strains, as well as recommendations for carcinogenicity strategies across different therapeutic modalities.

The 2027 STP Annual Symposium will provide discussions on exciting new discoveries in the study of cancer and development of therapeutics while equipping the toxicologist pathologist with practical tools for carcinogenicity assessment. In addition to the scientific sessions, there will be opportunities to obtain continuing education, browse poster presentations, attend a mystery slide session, and more. Hoping you join us in Denver!

Program Agenda


Sunday, June 27

STP Satellite Symposium (AM)

CE Course  (Half Day)

  • CE1 (PM): Digital Pathology in Toxicologic Pathology: From First Whole Slide Images through Validation to Advanced AI

Exhibits and Poster Sessions Open & Welcome Reception (PM)


Monday, June 28

Symposium Welcome and Keynote

  • Session 1 (AM): Cancer Biology and Mechanisms

    Co-Chairs: Drs. Dinesh Bangari and Anoop Kavirayani

    Insight into the mechanisms of cancer biology is important for the development of newer precision therapies. The first session on cancer biology and mechanisms will feature discussions on the developmental origins of cancers, cellular plasticity, tumor microenvironment dynamics, and early-stage translational efforts which guide cancer drug discovery and safety assessment.

    Speakers featured in this session will discuss the developmental origins of pediatric cancers and novel therapeutic targets. Talks will highlight preclinical animal models with clinical correlates and feature cross-species discovery and translational work with an emphasis on comparative pathology and animal models of disease. The session will also feature talks on the morphologic and molecular characterization of immune and non-immune cells of the tumor microenvironment, and the role of epithelial regenerative programs in cancer pathogenesis. The latter talk will highlight a highly plastic, de-differentiated cancer cell state that drives cancer progression and treatment resistance in pulmonary and pancreatic adenocarcinoma. The session will close with a case study on tumorigenesis in immunosuppressed nonhuman primates and its translational implications.

Exhibits and Poster Sessions Open

  • Session 2 (PM): Discovering Novel Cancer Therapeutics

    Co-Chairs: Drs. Elizabeth Clark and Famke Aeffner

    Abstract: Advances in tumor biology, therapeutic modalities, and preclinical models continue to create new opportunities for cancer drug discovery. This session will highlight complementary approaches to identifying and evaluating novel oncology therapeutics, with an emphasis on the contributions of pathology and translational science. The presentations will begin with a discussion of novel payload discovery for antibody-drug conjugates (ADCs), including efforts to expand beyond established payload classes. The application of in vivo mouse models in cancer research will then be explored from a comparative pathologist’s perspective, highlighting their strengths and limitations in studying tumor biology, assessing therapeutic response, and supporting clinical translation. Expanding beyond traditional laboratory animal models, naturally occurring cancers in companion dogs will be discussed as a source of translational insights for oncology drug discovery. Finally, the application of ‘omics data to support drug discovery and the development of novel therapeutic modalities will be explored. Together, these presentations will illustrate how emerging technologies, comparative biology, and integrated data can contribute to the discovery and preclinical development of novel cancer therapeutics.

Annual Business Meeting and Town Hall


Tuesday, June 29

  • Session 3 (AM): Toxicologic Pathology and Safety Assessment of Oncology Therapeutics

    Co-Chairs: Drs. Aaron Sargeant and Daher Ibrahim Aibo

    Oncology drug development is rapidly evolving as increasingly complex and highly targeted therapeutic modalities introduce distinct challenges for nonclinical safety assessment and translation to patients. This session will examine how toxicologic pathology, mechanistic understanding, and integrated safety strategies can support the development of radioligand therapies, chimeric antigen receptor T-cell therapies, T-cell engagers, targeted protein degraders, and antibody-drug conjugates. Speakers will highlight modality-specific mechanisms of toxicity, target- and tissue-related vulnerabilities, translational considerations, and approaches for early identification and mitigation of risk. Case examples and emerging data will illustrate how pathology findings can be interpreted within the context of pharmacology, biodistribution, immune activation, payload effects, and clinical relevance. The session will also address current challenges, evolving best practices, and opportunities to strengthen cross-disciplinary decision-making across discovery and development. A concluding panel discussion will integrate perspectives across modalities and consider how innovative tools and mechanistic insights can improve safety assessment while enabling the advancement of transformative oncology therapeutics.

Exhibits and Poster Sessions Open

Career Development Workshop (PM)

  • Mystery Slide Session

    Co-Chairs: Drs. Emily King, Victoria Laast, and Mee Ja Sula

    Put your diagnostic skills to the test in this interactive Mystery Slide Session centered on the 2027 Annual Meeting theme of cancer. Attendees will work through a selection of challenging and educational neoplastic cases relevant to toxicologic pathology, integrating cytomorphology and histomorphology with case history and other supporting information to develop a diagnosis and differential considerations. Cases will highlight diverse tumor types and diagnostic challenges and will provide opportunities to discuss distinguishing morphologic features, biologic behavior, and relevance to preclinical safety assessment. Following audience evaluation of each case, presenters will reveal the diagnosis and lead a discussion of key diagnostic features and take-home points. This engaging, case-based session is designed to encourage audience participation while sharpening diagnostic skills and expanding familiarity with the spectrum of neoplastic pathology encountered by toxicologic pathologists.


Wednesday, June 30

  • Session 4 (AM): Evolving Carcinogenicity Hazard Assessment: Integrated Weight-of-Evidence Frameworks across Sectors

    Co-Chairs: Drs. Arun Pandiri and Thomas Nolte

    This scientific session explores the paradigm shift in carcinogenicity testing from traditional two-year rodent bioassays to integrated, interdisciplinary, and multimodal Weight-of-Evidence (WoE) approaches. Driven by decades of rodent bioassay experience, technological advancements and evolving regulatory frameworks, it unites diverse perspectives across industry, pharmaceuticals, agrochemicals, environmental exposures, and regulatory bodies to redefine safety assessments. The session will introduce regulatory frameworks and integrating molecular data for early hazard identification. The next focus is the ICH S1B(R1) amendment, contrasting industry and regulatory experiences using WoE assessments of human carcinogenic hazard. Following intermission, the focus shifts the ReCAAP (Rethinking Chronic Toxicity and Carcinogenicity Assessment for Agrochemicals Project) initiative for agrochemicals. Speakers highlight new approach methodologies (NAMs), refined uncertainty factors, and risk management modernize chemical safety evaluation. The session concludes with practical WoE case studies exemplifying the translational relevance of mechanistic and toxicologic pathology findings. Collectively, these presentations show how multidisciplinary insights into the nature of findings and robust WoE frameworks establish more efficient, predictive, ethical, and translationally relevant carcinogenicity assessment. Attendees, particularly toxicologic pathologists, tasked with steering and integrating data across disciplines, will learn to implement these next-generation strategies to successfully navigate the regulatory landscape.

Exhibits and Poster Sessions Open

  • Session 5 (PM): Rodent Carcinogenicity Assessments: They Still Have a Role!

    Co-Chairs: Drs. David Garcia-Tapia and Marie Bockenstedt

    As drug development evolves, questions remain regarding the role of rodent carcinogenicity studies in assessing human cancer risk. Chaired by Drs. David Garcia-Tapia and Marie Bockenstedt, this session will provide a practical, pathology-focused review of contemporary carcinogenicity assessment strategies and their application across diverse therapeutic modalities.

    Presentations will begin with an overview of conventional 2-year rodent carcinogenicity studies, including study design considerations, common neoplastic and non-neoplastic findings, and approaches interpreting positive study outcomes. Insights into commonly used rat strains and strain-specific background lesions that influence study interpretation will be presented. The session will examine the study design, background tumor profiles, positive controls, and its role within modern carcinogenicity testing paradigms of the RasH2 transgenic mouse model. Finally, speakers will discuss contemporary recommendations for carcinogenicity assessment strategies across small molecules, biologics, and other therapeutic modalities.

    Throughout the session, practical concepts covered include histopathology examples, updates tumor nomenclature (INHAND), interpretation of common findings (i.e. hepatic altered foci), carcinogenicity statistics, and mechanistic approaches used to evaluate the human relevance of rodent tumor findings. Attendees will gain practical tools carcinogenicity study evaluation to integrate pathology findings into modern risk assessment and regulatory decision-making.

Awards and Recognition Ceremony

President’s Reception

Meeting Materials & Attendee Resources

Meeting publications, including the final Program, attendee list, committees, interest groups, and ancillary meeting schedules, will be posted on the Meeting Materials page when available.

STP members will use their regular logins to access this page. Nonmember attendees will receive logins and passwords to access this page.

  •  11190 Sunrise Valley Drive,
    Suite 300, Reston, VA 20191